ArticleInfection and drug resistance2020
Microbiological Characteristics of Carbapenem-Resistant
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Optimisation and validation of capture mNGS for predicting antimicrobial resistance.EBioMedicine · 2026Article
- Comprehensive genomic analysis of carbapenem-resistant Citrobacter freundii and characterization of a co-carrying blaBMC microbiology · 2026Article
- Genetic diversity of KPC-2-producing Klebsiella pneumoniae complex from aquatic ecosystems.World journal of microbiology & biotechnology · 2024Article
- Resistome and Genome Analysis of an Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Genomic characterization of two carbapenem-resistantFrontiers in cellular and infection microbiology · 2023Article
- Phenotypic and genotypic detection of resistance mechanisms in carbapenem-resistant gram-negative bacteria isolated from Egyptian ICU patients with first emergence of NDM-1 producingIranian journal of microbiology · 2022Article
- ST11 Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Targeted Elimination ofInfection and drug resistance · 2022Article
- Resistance Phenotype and Molecular Epidemiology of Carbapenem-ResistantInfection and drug resistance · 2022Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Emergence of NDM-5-Producing Carbapenem-ResistantInfection and drug resistance · 2020Article
- Carbapenemase-ProducingFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the molecular characteristics of carbapenem-resistant MATERIALS AND
methodsForty-three sequential non-duplicate CRE strains (including 33
resultsThe results of antimicrobial susceptibility testing indicated that 43 CRE strains were resistant to most of the antimicrobial agents, except tigecycline and colistin. Overall, 93%, 93%, and 97.7% of these strains were resistant to imipenem, meropenem, and ertapenem, respectively. PCR and DNA sequencing indicated that 67.4% (29/43) were
conclusionOur study indicated the dissemination of CRE between the tertiary hospitals and secondary hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.